Can a diabetes drug help PAH patients walk farther?
NCT ID NCT03617458
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether metformin, a common diabetes drug, along with a text-message activity program, could help people with pulmonary artery hypertension (PAH) walk farther and feel better day-to-day. 73 adults with PAH took part. The goal was to see if these interventions improved walking distance or daily function over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metformin
- What this could lead to
- If successful, this could point toward a new way to ease symptoms and improve daily function for people with pulmonary artery hypertension.
- What could go wrong
- This is a small, early-phase trial with only 73 participants, so results may not apply to everyone. Metformin is generally safe but can cause stomach upset or rare side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tiny study aims to unlock clues in rare lung disease
- Balloon in the womb: new hope for babies with severe birth defect?
- Researchers dive into why scleroderma and lung hypertension weaken the heart
- New MRI technique could make heart procedures safer and faster
- Could sotatercept help PAH patients breathe easier?
- Scientists probe blood flow secrets in aging and illness